Cambridge Investment Research Advisors, Inc.
Position in GUTS — Fractyl Health, Inc.
CIK 1419186
FAIRFIELD, IA
Position in GUTS
as of Mar 31, 2026
· filed Apr 30, 2026
Position Value
$29,312
-$111,488 QoQ
Shares Held
64,000
0.0% QoQ
Ownership
0.040%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cambridge Investment Research Advisors, Inc. holds $50,208,596 across 75 Biotechnology names. GUTS ranks #69 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,955 | $7,124,545 | |
| 2 | EXEL |
Exelixis, Inc.
|
159,749 | $6,851,634 | |
| 3 | NKTR |
Nektar Therapeutics
|
56,055 | $4,033,157 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,832 | $3,733,396 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
284,704 | $2,183,679 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
29,059 | $2,157,921 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
37,992 | $1,807,279 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
42,754 | $1,723,413 |
All Filings in GUTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,312 | 64,000 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $140,800 | 64,000 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||